NCT05147558View on ClinicalTrials.gov

A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 23, 2021

Primary Completion Date

December 23, 2025

Study Completion Date

December 23, 2025

Conditions
Uterine CarcinosarcomaAdvanced Uterine Carcinosarcoma
Interventions
DRUG

Pembrolizumab

Pembrolizumab (200mg every 3 weeks, intravenously)

DRUG

Lenvatinib

Lenvatinib (20mg once daily orally)

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (Limited protocol activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre

11725

Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities), Commack

07920

Memorial Sloan Kettering Basking Ridge (Limited protocol activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited protocol activities), Montvale

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER